English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Neoadjuvant chemotherapy (NACT), initially used to downstage breast cancer, may achieve pathologic complete response (pCR) in patients with no residual invasive breast or axillary disease (1). An increasing number of indications for NACT have been recently described; in addition to downstaging, NACT may benefit patients with human epidermal growth factor receptor (HER)2positive or triple-negative stage II–III breast cancer and hormone receptor-positive (HR+) patients with an explicit need for chemotherapy (2). NACT did not improve survival in patients with similar baseline characteristics and chemotherapy regimens when compared with adjuvant Original Article

Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response